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ABSTRACT. In the past, special guidelines and protective measures have been introduced to 
protect hospital workers during the handling of antineoplastic agents; nevertheless, it was 
found that they did not prevent the uptake of these toxic compounds. In response, additional 
protective measures were introduced, including adaptations of the laminar downflow hood, 
use of special masks, use of double pairs of gloves, and replacement of ampules with vials. 
In the current study, the authors compared the effects in these additional measures with 
results of a previous study. Cyclophosphamide, 5-fluorouracil, and methotrexate constituted 
81 % of the antineoplastic agents prepared; therefore, the investigators monitored these 
compounds again by personal air sampling and by determining the levels of contamination 
on masks and gloves. Cyclophosphamide in the urine of workers was also measured. During 
preparation, investigators concluded that there were lower concentrations of cyclophos­
phamide in the air than had occurred in the previous study. Replacement of ampules with 
vials (i.e., 5-fluorouracil) resulted in a significantly diminished contamination of latex gloves. 
Cyclophosphamide was detected in urine samples provided by six of nine technicians; the 
maximum amount excreted over 5 d was 2.6 [xg. The mean cyclophosphamide excretion/d 
was not significantly lower than that found in the previous study (0.16 fig and 1.44 |ig, 
respectively). Despite an intensified hygienic regimen, exposure to antineoplastic agents 
cannot be reduced if the reasons for exposure remain unknown.
IN THE NETHERLANDS, special guidelines and pro­
tective measures were introduced about 10 y ago to 
protect hospital workers from health risks associated 
with handling antineoplastic agents.1 Recently, howev­
er, these measures were amended.2 Other countries al­
so promote protective guidelines.3-6 Nevertheless, the 
results of several studies have shown uptake of antineo­
plastic agents in hospital workers who have followed 
the guidelines.7-15
In our recent study of the effectiveness of the protec­
tive measures, we showed that, during preparation, cy­
clophosphamide (CP) was detected in the air of the 
working environment at concentrations of < 0.04-10.1 
jig/m3.7 Contamination of, and permeation through,
latex gloves were found for the three drugs studied: (1 ) 
CP, (2) 5-fluorouracil (5FU), and (3) methotrexate 
(MTX). In addition, we detected CP in urine samples of 
some workers. The results showed that even though pro­
tective measures were taken, exposure to these com­
pounds occurred nonetheless. More important, the pro­
tective measures did not prevent uptake of CP. Investi­
gators suggested that inhalation was of minor impor­
tance with respect to internal exposure, compared with 
other presumably dermal routes.
These results led us to introduce additional protective 
measures in the hospital. The working aperture of the 
laminar downflow hood was reduced by enlargement 
of the viewing screen, and it was decided that the phar-
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macy technicians should use double pairs of gloves and 
a special mask. In addition technicians used vials, 
instead of ampules, for 5FU preparation. In the current 
follow-up study, we investigated the effects of these 
additional measures. We obtained personal air samples 
and analyzed them for the presence of CP, 5FU, and 
MTX. We studied permeation into latex gloves by ana­
lyzing the contamination of both the inner and outer 
gloves, and uptake of CP was determined by analysis of 
unmetabolized CP in urine.16 We compared the results 
of this study with the results of the previous study.
r
Material and Method
Study design. Nine pharmacy technicians were in­
volved in drug preparation; eight of these technicians 
were also involved in our previous study/ and their 
codes were the same. They prepared drugs in a laminar 
downflow hood on 5 successive days (i.e., Monday to 
Friday). For personal protection, the technicians wore 
latex gloves, hair nets, and special clothes. In contrast 
with the previous study, all technicians used a double 
pair of latex gloves and a special mask. The technicians 
were aware of the new study design and monitoring 
process. Any possible effect of this knowledge on their 
behaviors was not expected because they continued 
work as usual. The amounts of CP, 5FU, and MTX pre­
pared during this study were 24, 195, and 5 g, respec­
tively (Table 1). These compounds contributed to 81% 
of the anti neoplastic agents prepared. Cyclophospha­
mide, 5FU, and MTX were packed in vials.
Air sampling. We performed personal air sampling 
exactly in the manner we had done in our previous 
study/ We took the samples from all nine technicians 
on 5 successive days.
Masks. We collected the super-sigma 5005-V masks 
(Filgif, Groeneveld-Dordrecht B.V. [Dordrecht, the 
Netherlands]) after drug preparation so that no contami­
nation with other materials (e.g., the gloves) was 
possible. We packed the masks in aluminum foil unti 
time of sample preparation.
Glove contamination. The technicians wore double 
pairs of Ansell Gammex latex sterile surgical gloves 
(Ansell Medical [München, Germany) at all times dur­
ing drug preparation. After they prepared the drugs, we 
collected the pairs of gloves separately.
Urine sampling. We collected urine aliquots during 
the 5-d period, starting at the beginning of the time of 
drug preparation. The urine volumes and excretion 
periods were registered. We stored the urine samples at 
-20 °C until the time the samples were prepared.
Sampling procedures, sample preparation, and 
analysis. Sampling procedures, sample preparation, and 
analysis are described elsewhere.8'9'16 The masks were 
cut into pieces, and we extracted them by sonication 
during a 90-in period, after which we shook them for 10 
min with 250 ml of a 0.03-M sodium hydroxide solu­
tion. We then used extracts for direct analysis (i.e., 5FU 
and MTX) or for further clean-up (i.e., CP).
Statistical analysis. We used SAS software (version 6.06) 
to conduct the statistical analysis. We quantified cor-
Table 1.—Amounts (mg) of Cyclophosphamide (CP), 
5-Fluorouracil (5FU), and Methotrexate (MTX) Prepared 
by Technicians
Tota I
Technician Day CP 5FU MTX
1 Mon 900 2 600 0
Tue 650 1 100 0
Wed 0 38 000 0
Thu 0 0 75
Fri 0 1 000 30
2 Mon 1 250 1 100 0
Tue 1 000 0 0
Wed 500 0 0
Thu 0 25 000 0
Fri 0 0 0
3 Mon 600 4 500 0
Tue 600 0 0
Wed 0 1 600 0
Thu 600 0 0
Fri 0 25 900 0
5 Mon 1 200 19 900 0
Tue 0 4 950 30
Wed 1 150 0 0
Thu 600 0 0
Fri 0 900 0
6 Mon 1 000 5 900 0
Tue 650 0 0
Wed 550 0 0
Thu 900 900 0
Fri 0 17 900 0
7 Mon 0 4 800 0
Tue 1 200 0 0
Wed 0 0 0
Thu 0 0 0
Fri 0 1 500 15
8 Mon 250 800 0
Tue 900 1 100 0
Wed 400 0 0
Thu 0 0 75
Fri 0 500 60
9 Mon 650 800 0
Tue 3 000 900 0
Wed 0 0 4 910
Thu 400 25 000 0
Fri 1 200 900 0
10 Mon 1 000 6 700 0
Tue 350 0 0
Wed 1 600 0 0
Thu 900 900 75
Fri 300 0 30
*****
24 300
9
95 150 
70
iiiH Wi
5 :
2
n u m m i» m i
*As a of all s prepared.
m m ■m iw m
relation with Spearman's rank correlation coefficient; p 
values refer to two-tailed tests, and only p values £.05 were 
considered significant. In the case or a nondetectable 
amount, we used half of the detection limit.
Results
Air samples. We detected no 5FU and MTX on the 
filters of the personal air samples. We found CP on 2 d; 
the air concentrations were 0.06 fxg/m3 (technician 2 on 
Wednesday) and 2.0 jag/m3 (technician 8 on Tuesday). 
On both of these days, technicians had prepared CP. The
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limits of detection, depending on the amounts of air 
sampled/ ranged from 0.02 |ig/m3 to 0.15 |ig/m3 for CP, 
1.6 fig/m3 to 9.9 |ig/m3 for 5FU, and 3.8 fig/m3 to 24 
fig/m3 for MTX.
Masks. Ten of 45 masks were contaminated with CP 
(Table 2). The amounts of CP ranged from less than 0.2 |ig 
to 8.8 fig. Cyclophosphamide was also present on 2 
masks worn by technicians who were not involved in its 
preparation. We did not find a correlation between level 
of contamination and the amount of drug prepared or 
number of vials used. One mask was contaminated with 
15 |ig 5FU, but no masks were contaminated with MTX. 
No drugs were detected on the masks worn by five 
technicians. The limits of detection per mask were 0.2 fig 
for CP, 5 jo.g for 5FU, and  13 |Lig for MTX.
Glove contamination. The outer pairs of latex gloves 
were most often contaminated with CP (26 pairs) and 5 
FU (9 pairs) (Table 3). The amounts of CP and 5FU 
ranged from less than 0.13 fig to 140 fig (median: 1.2 
jig) and from less than 2.0 |ig to 450 jig (median: < 2 
fig), respectively. One outer pair of gloves was contami­
nated with 94 jag MTX (i.e., technician 9 on Wednes­
day). We found 5FU on 1 outer pair of gloves worn by 
a technician who did not prepare 5FU, and we found 
CP on 3 pairs of gloves worn by technicians who did 
not prepare CP. The levels of contamination of the outer 
pairs of gloves were correlated significantly with the 
amount of drugs prepared (CP: r = .60, p = .0001; 5FU: 
r = .32, p = .03) and the number of vials used (CP: r = 
.63, p = .0001; 5FU: r= .47, p= .001). We found that 
7 inner pairs of latex gloves were contaminated with CP 
only (Table 3); amounts of CP ranged from less than 
0.13 |ig to 9.1 fig (median: < 0.13 |ig). We found CP on 
1 inner pair of gloves worn by a technician who did not 
prepare CP. The level of contamination of the inner 
pairs of gloves was not correlated significantly with the 
amounts of drugs prepared or with the number of vials 
used. We did not quantify the 5FU contamination of the 
inner latex gloves because there was interference by 
coeluting compounds during analysis of the samples. 
The limits of detection per pair of gloves for CP, 5FU, 
and MTX were 0.13 fig, 2 j_Lg, and 10 fig, respectively.
CP in urine. We detected CP in urine samples pro­
vided by six technicians (Table 4); the maximum 
amount excreted over 5 d was 2.6 jig. All technicians 
prepared CP during at least 1 d (mean: 3 d). We found 
no correlation between the total amount of CP excreted 
over 5 d and the amount of CP prepared. Even when we 
averaged the amount of CP prepared by the number of 
days of preparation, the limit of detection was approxi­
mately 0.25 ng/ml urine.
Discussion
In a previous study, we detected CP in personal air 
samples on 4 of 17 d.7 The air concentrations ranged 
from 0.04 fig/m3 to 10.1 fig/m3. In the present study, we 
once again detected CP, although less frequently (i.e., 2 
of 45 d), and the concentrations were significantly 
lower (Wilcoxon test: p = .005). In both studies, we de­
tected no 5FU and no MTX in personal air samples.
Table 2.—Contamination with Cyclophosphamide (CP) 
and 5-Fluorouracil (5FU) of Masks Used during 
Drug Preparation*
Technician Day
Contamination (fig)
CP 5FU
1 Mon 5.5 <5
Tue 2.2 <5
Wed < 0.2 15
5 Mon 0.2 <5
Thu 0.3 <5
Fri 8.8 < 5
8 Mon 2.0 <5
Tue 1.8 < 5
Thu 1.8 <5
9 Tue 6.2 <5
r * »  *Fri 5.7 < 5
*Only masks with detectable amounts of one of the drugs 
measured are indicated.
Adaptations of the laminar downflow hood may have 
been responsible for the observed decrease in air con­
centrations of CP. Obviously, the release of aerosols 
could not be prevented totally, as was demonstrated by 
the presence of CP on the masks. We did not detect 
MTX on the masks, but we detected 5FU once—after 
the preparation of a large amount (i.e., 21 000 mg) of 5
FU.
In both the present and previous studies we observed 
minimal MTX contamination of the outer latex gloves. 
In the present study, we found MTX once when a large 
amount (i.e., 4 910 mg) of MTX was prepared. In our 
previous study, we found 5FU contamination of the 
outer latex gloves on 11 of 17 d (range: < 4.0-620 fig), 
whereas in the present study we observed 5FU contam­
ination on 9 of 45 d (range: < 2.0-450 |ig). Both the fre­
quency with which outer gloves were contaminated 
(Fisher's exact test: p = .04) and the level of contamina­
tion (Wilcoxon test: p = .001) were decreased signifi­
cantly. Whether the diminished contamination of the 
outer gloves with 5FU resulted from use of vials— 
instead of ampules—needs further investigation. Per­
haps the breaking of ampules causes a release of aero­
sols, thus resulting in contamination of the gloves.7
During our previous study, we found CP contamina­
tion of the outer latex gloves on 8 of 17 d (range: < 
0.08-9.6 |ig).7 During the current study, we observed 
contamination with CP on 26 of 45 d (range: < 0.13- 
140 fig). We found no significant differences between 
the frequency of determining contamination of the 
outer gloves and the level of contamination in the pre­
sent and previous studies. Breaking of ampules played 
an important role in our study; this is not surprising be­
cause in both studies technicians used vials in the 
preparation of CP. In our previous study, technicians 
wore cotton gloves under latex gloves, and we studied 
the permeation of CP, 5FU, and MTX through the latex 
gloves. In the present study, we replaced the cotton 
gloves with latex gloves, which were identical to the
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Table 3.—Contamination with Cyclophosphamide (CP) and 5-FIuorouracil (5FU) of Gloves 
Used during Drug Preparation*
CP contamination ((.ig/pair)
5FU contamination 
((ig/pair)
Technician Day Outer gloves Inner gloves Outer gloves
1 Mon 4.1 < 0.13 14
Tue 3.7 < 0.13 <2
Wed < 0.13 2.4 9.1
2 Mon 1.9 < 0.13 < 2
Tue < 0.13 < 0.13 26
Wed 0.37 < 0.13 <2
3 Mon 54 < 0.13 < 2
Tue 1.7 <0.13 < 2
Thu 2.1 < 0.13 <2
«rri < 0.13 <0.13 450
5 Mon 83 1.4 12
Wed 11 <0.13 <2
Thu 5.9 < 0.13 <2
6 Mon <0.13 <0,13 38
• • Tue 0.27 < 0.13 <2
Thu 30 < 0.13 <2
wm vFri 2.6 <0,13 2 00
7 Mon < 0.13 < 0.13 37
wwmlue 2.9 < 0.13 < 2
8 Mon 2.4 1.3 < 2
Vi ft*Tue 2.3 < 0.13 < 2
Wed 1.3 1.5 < 2
Thu 1.2 < 0.13 < 2
9 Mon 4.5 < 0.13 <2
Tue 70 < 0.13 <2
Wed 3.4 <0.13 <2
Thu 5.4 3.2 <2
Fri 140 9.1 17
10 Mon 0.73 <0.13 <2
Tue <0.13 1.3 <2
Wed 1.4 <0.13 <2
Fri 1.8 <0.13 < 2
*Only with detectable amounts of one of the zs measured are indicated.
yum »««* mm
Table 4.—Cumulative CP Excretion in Urine of Pharmacy 
Technicians and Amounts of Cyclophosphamide (CP) Prepared
Technician CP prepared (mg)
CP in urine 
(p.g/5d)
1 1 550 0.6
2 2 750 ND
3 1 800 ND
5
A
2 950 
} 1 nn
2.1
n *yt>
7
j 1 uu 
1 200
u«z
ND
8 1 550 0.6
9 5 250 1.1
10 4 150 2.6
All technicians 24 300 7.2
Note: ND = not detected.
ed with CP, therefore suggesting 100% permeation of 
CP. In the present study, we detected CP on 7 of 45 
inner pairs of latex gloves (range: < 2.0-9.1 (ig). We 
found no CP on the corresponding outer pairs of latex 
gloves from 2 of these contaminated pairs of gloves. As 
well, we found no correlation between level of conta­
mination on the inner latex gloves and the amount of 
CP prepared or the number of vials used. However, the 
sum of the amounts of CP contamination on the outer 
and inner latex gloves was correlated significantly with
56, p = .0001) and with
inner latex gloves was
outer gloves. In the present study, we found that perme­
ation also occurred through the outer latex gloves. In 
our previous study, 5 of 8 pairs of cotton gloves were 
contaminated with CP (range: < 0.08-73 fig). Four pairs 
of these contaminated cotton gloves corresponded to 4 
pairs of outer latex gloves, which were not contain inat-
the amount of CP prepared (r
the number of vials used (r = .60, p = .0001). The level 
of CP contamination on 
diminished significantly in the present study, compared 
with the results of the previous study (Wilcoxon test, p 
= .02). Because no difference was observed between 
both studies with respect to the frequency of contami­
nation of the outer gloves and the level of contamina­
tion with CP, we suggest that the diminished contami­
nation was caused by the use of latex gloves as inner 
gloves. In the previous study, we detected CP in 24-h 
urine samples provided by five of nine workers.7 In the 
present study, we found CP in urine samples provided 
by six of nine workers, but it should be noted that these
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samples were collected over a longer period of time 
(i.e., 5 d versus 1 or 2 d). We calculated daily mean 
amounts of CP found in urine and compared the results 
with the daily mean amounts of CP in urine calculated 
in our previous study. We found a decrease in mean CP 
excreted per day—from 1.44 jo,g in the previous study to 
0.16 jig in the current study. The difference, although 
large, was not significant (paired Wilcoxon test).
In this study, additional protective measures appeared 
to reduce the external exposure of technicians to CP and 
5FU. Methotrexate was barely detected; perhaps this 
resulted from a highér detection limit of the analytical 
method. To what extent each of the additional protective 
measures has contributed to this decrease remains 
unknown. Nevertheless, contamination of the latex 
gloves was reduced—possibly from use of vials, instead 
of ampules. Also, the filters in the personal air samplers 
contained such small amounts of CP, 5FU, and MTX that 
we can conclude that these chemicals were barely exis­
tent in the air of the working environment The question 
remains whether the use of double pairs of latex gloves 
diminished permeation of CP. Perhaps contamination 
with CP was decreased because CP permeated the inner 
pairs of latex gloves. This might have resulted in skin con­
tact and subsequent absorption.
Our aim in this study was to determine whether addi­
tional protective measures reduced the uptake of CP. It 
should be noted that a 90% reduction in exposure lev­
els is important—even if not significant. There might be 
several reasons for the absence of significance between 
both studies with respect to the amounts of CP in urine. 
The absence of significance was likely caused by large 
standard deviations that resulted from large interindi­
vidual differences; we even paired the individual values 
of the workers between both studies. Absence of signif­
icance likely resulted from the small group of workers 
(n = 8). In addition, there is no reason to expect high 
correlations with external dose when wide coefficients 
of variation for low exposure levels are observed. Nev­
ertheless, in the current study, the amounts of CP excret­
ed in urine were comparable with the results of urinary 
CP excretion reported in previously published studies of 
other groups of hospital pharmacy employees who 
worked under similar situations and who used compa­
rable protective measures.9,17
The question of whether exposure can be diminished 
by a reduction in handling is a difficult one. Normally, 
it is reasonable to assume a positive correlation be­
tween use and exposure. The question remains as to 
what extent diminished use will result in a reduction of 
exposure, because it is not at all clear how exposure 
occurs. The presence of environmental contamination 
may result in chronic exposure. We do not expect that 
diminished use will reduce the environmental contam­
ination present at a given moment in the working area. 
The results of this study indicate that, despite efforts in 
a hygienic regimen, exposure to antineoplastic agents 
cannot be reduced. Only when we know the exact rela­
tionship between sources of exposure, distribution, and 
absorption will we be able to further reduce the level of 
exposure to antineoplastic agents.
^  ^
^  «T* ^  ^  nP* *  ♦ p  <t *
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